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Abstract The ability to rapidly restore the integrity of a
broken skin barrier is critical and is the ultimate goal of
therapies for hard-to-heal-ulcers. Unfortunately effective
treatments to enhance healing and reduce scarring are still
lacking. A deeper understanding of the physiology of
normal repair and of the pathology of delayed healing is a
prerequisite for the development of more effective thera-
peutic interventions. Transition from the inflammatory to
the proliferative phase is a key step during healing and
accumulating evidence associates a compromised transi-
tion with wound healing disorders. Thus, targeting factors
that impact this phase transition may offer a rationale for
therapeutic development. This review summarizes mecha-
nisms regulating the inflammation–proliferation transition
at cellular and molecular levels. We propose that identifi-
cation of such mechanisms will reveal promising targets
for development of more effective therapies.
Keywords Macrophage  Fibroblast 
Bioactive lipid mediator  Reactive oxygen species 
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Introduction
Skin is the main barrier protecting us from the often hostile
environment. Upon injury, rapid closure of the wound and
prompt regeneration of the damaged skin are critical to
restore barrier function. Effective repair requires commu-
nication and interplay between many different cell types
and this process is precisely orchestrated and regulated at
multiple levels [1]. The wound healing process is usually
characterized as four sequential but overlapping phases:
haemostasis (0–several hours after injury), inflammation
(1–3 days), proliferation (4–21 days) and remodelling
(21 days–1 year) [1]. Deregulation of any of these steps
results in impaired healing, e.g., chronic hard-to-heal ulcers
or excessive scarring, which presents a major and
increasing health and economic burden to our society [2,
3]. Current treatments for impaired wound healing focus
mainly on optimisation of controllable healing factors, e.g.,
clearance of infection, mechanical protection and nutri-
tional support. Few targeted approaches have been
developed to date, including mainly topical application of
growth factors, unfortunately with limited clinical efficacy
[4]. Identification of new therapeutic targets and develop-
ment of more effective treatments are needed.
Transition from the inflammatory to the proliferative
phase represents a key step during wound healing. The
inflammatory phase is essential leading to haemostasis and
recruitment of the innate immune system, which defends us
against the attack of invading pathogens and help remove
dead tissues [1]. However, prolonged inflammation is
detrimental and may result in deregulated differentiation
and activation of keratinocytes, impeding the progress
through the normal stages of wound healing [2]. Severe
inflammation has also been associated with excessive
scarring [5]. Compared with the process of initiation and
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amplification of the inflammatory response, we know much
less about how inflammation is resolved during normal
wound healing, which is prerequisite for understanding the
pathogenesis of persistent inflammation in chronic wounds
[6]. Moreover, the next step, proliferation, is tightly con-
nected with the inflammatory response, and also plays an
important role in resolving inflammation. This review will
focus on the inflammation-proliferation transition in nor-
mal physiologic as well as in impaired wound healing and
highlight factors that can regulate this process at cellular
and molecular levels.
Physiologic skin wound healing
Wound healing is often described as a drama, with the
interplay of a multitude of different cell types, and is
precisely directed to serve the ultimate goal: prompt
healing [1]. Although many questions remain, extensive
studies in the field have provided a general picture about
this fundamental biological process.
Haemostasis phase
Once the skin gets injured, exposure of collagen initiates
the intrinsic and extrinsic clotting cascades. Thrombocytes
aggregate and trigger vasoconstriction to reduce blood loss,
which results in hypoxia, increased glycolysis and pH
changes [7, 8]. A blood clot is formed to fill up the wound
bed, which serves as a provisional wound matrix, providing
a scaffold for the migration of different cell players. After a
5- to 10-min vasoconstriction, blood vessels are dilated,
thrombocytes and leukocytes migrate into the provisional
matrix [1]. Degranulation of platelets activates the com-
plement cascade, which stimulates inflammatory cells and
kills bacteria [9]. Moreover, a variety of cytokines and
growth factors are released into the wound during this
stage, mediating the communication and synergizing the
activity of different cell players to accomplish the task of
healing. A classic view of cytokines and growth factors in
skin wound healing was summarized elsewhere [10].
Inflammation phase
In the inflammatory phase, involving mainly activation of
the innate immune system, neutrophils and monocytes
rapidly migrate into the injured skin. This phase is actually
concurrent with haemostasis, and described as the early
stage of wound healing [11]. As a consequence of injury,
resident skin cells, e.g., keratinocytes, macrophages, den-
dritic cells and mast cells, are exposed to danger signals,
which in general can be divided into two categories:
(a) damage-associate molecular patterns (DAMPs), i.e.,
molecules released by stress cells undergoing necrosis,
such as the intracellular proteins, DNA and RNA;
(b) pathogen-associated molecular patterns (PAMPs),
which are pathogen-specific molecules not found in the
host, e.g., bacterial essential polysaccharides and polynu-
cleotides [12]. Upon skin injury these danger signals are
recognized by pattern recognition receptors, among which
toll-like receptors (TLRs) are the best characterized ones.
TLRs are constitutively expressed on host cells and stim-
ulation of TLRs induces the activation of intracellular
signalling pathways, including the nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-jB) and
mitogen-activated protein kinases (MAPK) pathways,
which lead to the expression of a large number of genes,
including cytokines, chemokines and antimicrobial pep-
tides, to initiate and perpetuate the inflammatory response
(Fig. 1) [13, 14].
In response to chemokines, complement and by-prod-
ucts of bacterial degradation, neutrophils are recruited from
the circulation to the wound site in the early inflammatory
stage in a multistep process [1, 9]. Chemokines induce the
expression of adhesion molecules, e.g., intercellular adhe-
sion molecule 1 (ICAM1), vascular cell adhesion molecule
1 (VCAM1) and e-selectin (SELE), on endothelial cells,
which mediate the adherence of neutrophils to the wall of
blood vessels [15]. Adherence to endothelial cells and
exposure to chemokines change the cytoskeleton of neu-
trophils, which lead to neutrophil extravasation [15]. Once
outside the blood vessel, neutrophils are exposed to a
chemokine gradient within the skin and migrates towards
the higher concentration, the site where these chemokines
are released, i.e., the wound site. It is noteworthy that all
leucocytes, not only neutrophils, use this mechanism of
localisation [15]. If the wound does not get infected, neu-
trophils usually remain for 2–5 days [16]. They perform
phagocytosis to remove pathogens and cell debris [16].
After being engulfed into the phagosome of the neutrophil,
the microbe is killed and digested by toxic cationic
enzymes and oxygen metabolites [16]. Neutrophils also
produce cytokines, e.g., tumor necrosis factor (TNF)-a,
interleukin (IL)-1b and IL-6, to amplify the inflammatory
response [11]. Moreover, they exert debridement by
releasing a variety of antimicrobial substances, e.g.,
cationic peptides and proteinases [11].
Approximately 3 days after injury, monocytes are
recruited to the injury site, where they differentiate into
macrophages and support healing (Fig. 2). Macrophages
are important players facilitating the inflammatory–prolif-
erative phase transition during wound healing, and will be
discussed in a separate section.
In normal skin wound healing, the inflammation usually
lasts for 2–5 days and ceases once the harmful stimuli have
been removed; even though the immune responses
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continue through the whole procedure of wound healing,
evolving through progressive states of specific leukocyte
involvement and function (reviewed in [12]). The adaptive
immune system, the other arm of immunity, provides a
more delayed but specific response carried out by B and T
cells. B cells not only secret antibodies, but also impact
immune response by production of various cytokines and
growth factors, antigen presentation, regulation of T cell
activation and differentiation, and regulation of lymphoid
organization [17]. B cell has been shown to present in
wound tissue [18] and play a critical role in healing [19]. In
wound repair, T lymphocytes function as growth factor-
producing cells as well as immunological effector cells
[20]. Specific deficiency of CD4 or CD8 lymphocytes
changes the infiltration of inflammatory cells and the pro-
files of cytokine expression in skin wounds, while does not
impair wound closure in mouse [21]. A prolonged and
increased presence of T cells and a changed CD4-CD8 ratio
Fig. 1 Negative regulators of Toll-like receptor signaling. TLR2,
TLR4, TLR5, TLR9 activate myeloid differentiation primary-
response protein 88 (MyD88)-dependent pathway. MYD88-adaptor-
like protein (Mal) recruits MyD88 to TLR2 and TLR4. TLR3
activates TIR-domain-containing adapter-inducing interferon-b
(TRIF)-dependent pathway. In association with TRIF-related adaptor
molecule (TRAM), TLR4 can also activate TRIF-dependent pathway.
Upon stimulation, MyD88 recruits IL-1 receptor-associated kinase
(IRAK), which is activated by phosphorylation and then associates
with TNF receptor-associated factor 6 (TRAF6), leading to the
activation of transforming growth factor b-activated kinase (TAK1).
TAK1 further activates the transcription factors NF-jB and AP-1
through MAPK and NF-jB pathways, respectively. TRIF binds to
receptor-interacting protein 1 (RIP1) and TRAF6, also leading to the
activation of NF-jB and MAPKs. TRIF also activates interferon
regulatory factor 3 (IRF3) through TNFR-associated factor 3
(TRAF3). A plethora of inhibitory mechanisms have been identified
in TLR signaling: (i) interference of ligand binding, e.g., soluble
forms of TLR2 and TLR4 compete with membrane-bond forms of
TLRs for ligands binding; (ii) reduction of TLR expression, e.g.,
TGF-b suppresses the expression and function of TLR4; (iii)
degradation of TLRs, e.g., TRIAD3A binds to the cytoplasmic
domain of TLR4 and TLR9 and promotes their ubiquitylation and
degradation; (iv) inhibition of TLR downstream signaling, e.g.,
SOCS1, IRAKM, TOLLIP, IRAK2c/d, A20 and DUSP1; (v) change
of structures of target genes through chromatin remodeling and
histone modification, e.g., H2AK119 ubiquitylation and H3K27
trimethylation inhibit the expression of TLR-signal-targeted genes;
(vi) microRNAs can regulate TLR signaling by targeting TLRs,
downstream signaling proteins, related regulatory molecules, tran-
scription factors as well as genes induced by TLR signaling. The
figure was made with tools from www.proteinlounge.com
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have been observed in human chronic wounds [22]. Foxp3-
expressing regulatory T cells (Tregs) are a dynamic and
heterogeneous population of cells that control immune
responses and prevent autoimmunity. There are a large
number of Tregs presenting in the skin [23]. Recent studies
show that activated Tregs accumulate in skin wound, which
attenuate interferon (IFN)-c production and proinflammatory
macrophage accumulation, facilitating wound repair through
epidermal growth factor receptor (EGFR) pathway [24].
Recently, several cell types, which bridge between innate
and adaptive immunity, have been shown to play key roles
in skin wound healing. Upon injury, plasmacytoid dendritic
cells (pDCs) infiltrate in skin wounds at the same time as
neutrophils [25]. pDCs sense host-derived nucleic acids
released in the wound and transiently produce type I
interferons (IFN-a/b) via TLR7- and TLR9-dependent
mechanisms, which process is critical for the induction of
early inflammatory responses and re-epithelialization of
injured skin [25]. Langerhans cells (LCs) are a specialized
subset of epidermal dendritic cells, which serve as first-line
defender, contributing to epidermal immune surveillance.
Increased epidermal LCs has been observed at wound edges
during early phases of normal wound healing, although the
exact protective mechanism of these cells is unknown [26,
27]. Moreover, higher number of LCs in the epidermis of
diabetic foot ulcers has been reported to correlate with
healing outcome [27]. Different from the well-defined abT
cell, cdT cell is a subset of T cells expressing T cell antigen
recognition receptor (TCR) composed of c and d subunits.
The subpopulation of cdT cells in the epidermis is known as
dendritic epidermal T cells (DETC) [12]. In skin wounds,
cdT cells can recognize and eliminate damaged ker-
atinocyte, release growth factors, e.g., fibroblast growth
factor (FGF)-7, keratinocyte growth factor (KGF)-1 and
insulin-like growth factor (IGF)-1, which stimulate prolif-
eration of neighbouring healthy keratinocytes (reviewed in
[12]). In human acute wounds both ab- and cd- skin-resi-
dent T cells have been shown to actively produce IGF-1,
whereas skin-resident T cells isolated from chronic wounds
do not express IGF-1 and exhibit an unresponsive state [28].
Also, a subpopulation of cdT cells produces IFN-c,
enhancing the antimicrobial, antitumor and other functions
of NK and abT cells. Another subpopulation of cdT cells
produce IL-17 and induce expression of multiple host-de-
fense molecules in epidermal keratinocytes, promoting
wound healing [29].
The immune system plays an active role not only in the
inflammatory phase, but also throughout the whole wound
healing process. Compared with innate immunity, our
knowledge regarding the role of adaptive immunity in
Fig. 2 The roles ofmacrophage in wound healing. In the early phase of
wound repair, upon exposure to pro-inflammatory cytokines, interfer-
ons (IFNs), PAMPs or DAMPs, infiltrating monocytes and resident
macrophages are activated and mainly acquire a pro-inflammatory M1
phenotype. They perform phagocytosis of microbes, scavenge cellular
debris and produce pro-inflammatory mediators. Later during healing
process, IL4, IL-10, Glucocorticoids, Prostaglandins (PGs) and
modulators of glucose and lipid metabolism induce macrophages to
transit to a reparative M2 phenotype, which secret anti-inflammatory
mediators and growth factors. Macrophages also remove neutrophils in
the wounds by phagocytosis, a central element to induce the M1-M2
phenotype switch of macrophages. The figure was made with tools
from www.proteinlounge.com
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wound healing is sparse. Understanding the delicate
immunologic balance is an important task for research on
wound healing. This review will primarily focus on the role
of innate immunity in relation to inflammation.
Proliferation phase
As the inflammation subsides, proliferation becomes a
major theme with the focus on covering the wound surface
(i.e., re-epithelialization), restoring the vascular network
and forming granulation tissue.
Re-epithelialization requires migration and proliferation
of keratinocytes. In a few hours to 1 day after injury, the
existing wound-edge keratinocytes start to migrate. To
generate more cells to cover the wound, keratinocytes at
the basal layer of the wound edge and epithelia stem cells
from nearby hair follicles or sweat glands start proliferating
approximately 2–3 days after injury [30]. Migration is
triggered by loss of contact inhibition and physical tension
at cell adhesion structures, i.e., desmosomes and
hemidesmosomes, which activates membrane-associated
kinases, thus leading to increased membrane permeability
for calcium. This is a signal for reorganization of
cytoskeleton driving migration. Meanwhile, the migrating
cells are released from their original sites by collagenase
and elastase. Details for this process were summarized
elsewhere [31]. Migration stops when the cells get in
contact and new adhesion structures are formed. Ker-
atinocytes secrete proteins to rebuild the basement
membrane [31]. Re-epithelialization can be stimulated by a
variety of wound–related signals, e.g., nitric oxide, which
is mainly synthesized by macrophages [32], cytokines and
growth factors, including epidermal growth factor (EGF),
KGF, IGF-1, and nerve growth factor (NGF), secreted from
multiple cell types in the wounds [10].
Restoring the network of blood vessels is important, since
nutrients and oxygen are needed during wound repair. The
process of new blood vessel formation, also known as ‘an-
giogenesis’, is initiated by growth factors, e.g., vascular
endothelial growth factor (VEGF), platelet-derived growth
factor (PDGF), basic fibroblast growth factor (bFGF), and
the serine protease thrombin in the wounds, which activate
the endothelial cells of existing vessels [33]. After secreting
proteolytic enzymes to dissolve the basal lamina, the
endothelial cells escape from the existing vessels, proliferate
and migrate towards the source of the angiogenic stimulus
[33]. These sprouts form vessel lumen, differentiate into
arteries and venules and mature by recruitment of pericytes
and smooth muscle cells [33]. In addition, bone marrow-
derived endothelial progenitors can also form vessels de
novo, a process known as vasculogenesis, [11, 34].
In the proliferation phase, the provisional wound matrix
formed during haemostasis is replaced by granulation
tissue, consisting of a large amount of fibroblasts, granu-
locytes, macrophages, blood vessels, in complex with
collagen bundles, which partially recovers the structure and
function of the wounded skin [35]. Fibroblasts play a
central role in the formation of the granulation tissue,
which migrate mainly from the nearby dermis to the wound
in response to cytokines and growth factors, e.g., PDGF,
transforming growth factor (TGF)-b and bFGF, produced
by platelets and macrophages in the wounds [35, 36]. If the
wound condition is long lasting, fibroblasts in the wounds
may also originate from fibrocytes, which is a group of
bone marrow-derived mesenchymal progenitor cells [37,
38]. Circulating fibrocytes migrate to regions of skin injury
and promote healing not only by contributing to a subset of
fibroblasts in the wounds, but also by producing cytokines,
chemokines, and growth factors, serving as antigen pre-
senting cells as well as enhancing angiogenesis [39]. After
migrating into the provisional wound matrix, fibroblasts
proliferate and produce proteinases, e.g., matrix metallo-
proteinases (MMPs), to degrade provisional matrix [40,
41]; while depositing collagen and other extracellular
matrix (ECM) components, e.g., proteoglycans, hyaluronic
acid, glycosaminoglycans, and fibronectin, to form granu-
lation tissue [5], which fill up the wound gap and provide a
scaffold for cell adhesion, migration, growth and differ-
entiation during wound repair [42, 43].
Remodelling phase
The remodelling phase starts at the end of the granulation
tissue development. Mechanical tension and cytokines,
e.g., TGF-b, drive fibroblasts to differentiate into myofi-
broblasts, which express a-smooth muscle actin (SMA)
and contract the wound [44]. Myofibroblasts undergo
apoptosis when healing is complete [5]. At this phase, the
quickly produced collagen III in the ECM is replaced by
the collagen I, which has a higher tensile strength but
takes longer time to deposit. The number of new blood
vessels and the blood flow decline. A mature avascular
and acellular environment is formed [45]. Some skin
components, e.g., hair follicles and sweat glands, cannot
be recovered after serious injury; and the healed skin can
only achieve maximum *80 % of the original tensile
strength [46].
Factors regulating the transition
from inflammation to proliferation during wound
healing
Excessive and prolonged inflammation results in delayed
healing and increased scar formation. However, compared
with the knowledge about the initiation and amplification
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of inflammatory response, we know little about how
inflammation is controlled and timely resolved, which is
critical to enable progression into the proliferative phase.
Here, we focus on reviewing factors deemed important for
resolving inflammation and promoting proliferation, thus
facilitating the transition from inflammation to prolifera-
tion during skin wound healing.
Macrophages
In the intact skin, macrophages are the most abundant
haematopoietic population, performing immune sentinel
and homeostatic functions [47]. Upon skin injury, a large
amount of monocytes exit the circulation and enter the
wound site. Both infiltrating and skin-resident macro-
phages are activated by local microenvironmental signals
and further develop into various subpopulations, defined by
their distinct functional phenotypes [48]. PAMPs expressed
by microbes and DAMPs produced during cellular stress in
synergy with natural killer cell-derived IFN-c polarize
macrophages into classically activated macrophages (M1
subset), which promote Th1–Th17 immunity, host defense
and antitumor immunity [49]. In contrast, cytokines such as
IL-4 and IL-13 drive the formation of alternatively acti-
vated macrophages (M2 subset), which suppress
inflammation and antitumor immunity, regulate glucose
metabolism as well as facilitate wound repair [50–53]. TLR
ligands together with immunoglobulin G immune com-
plexes induce the development of regulatory macrophages,
which produce IL-10 and TGF-b1 and play an immuno-
suppressive role [49]. This is to name just a few
subpopulations with distinct functions and generally mac-
rophages are considered to have the ability of either induce
or suppress the immune response. Importantly, they man-
ifest substantial plasticity in their phenotypes and
functions, that is, they can readily switch from one func-
tional phenotype to another in response to different
microenvironment stimuli [54–56]. These properties make
macrophages versatile players to assist and orchestrate all
stages of wound healing (Fig. 2).
In the early phase of wound repair, upon exposure to pro-
inflammatory cytokines, IFNs, microbial products or
DAMPs, infiltrating monocytes and resident macrophages
are activated and mainly acquire a pro-inflammatory M1
phenotype (Fig. 2) [57]. They perform phagocytosis of
microbes, scavenging of dead cells and cellular debris and
produce pro-inflammatory mediators, such as IL-1, IL-6, IL-
12, TNFa, inducible nitric oxide synthase (iNOS), as well as
chemokines to recruit additional leukocytes [10, 48, 58].
Later during the healing process, macrophages transit
from a pro-inflammatory M1 to a reparative M2 phenotype,
expressing anti-inflammatory mediators, e.g., IL-1R
antagonist, decoy IL-1 receptor type II and IL-10, and
growth factors, e.g., TGFb, VEGF and IGF1, promoting
fibroblast proliferation, ECM synthesis and angiogenesis
(Fig. 2) [59, 60]. This M1–M2 transition is critical for the
resolution of inflammation and tipping the balance to tissue
repair [49]. As mentioned above, IL-4 and IL-13 are the
canonical factors inducing the M2 phenotype, however,
recent studies show that they are not necessary for modu-
lating macrophage phenotypes in wounds in vivo [61, 62].
Anti-inflammatory cytokines (e.g., IL-10), glucocorticoids,
prostaglandins, and modulators of glucose and lipid
metabolism may also induce M2-like phenotypes. Impor-
tantly, the defection of M1–M2 phenotype transition of
macrophages has been implicated in the pathogenesis of
chronic wounds. For example, iron overload drives mac-
rophages into an unrestrained pro-inflammatory M1-
activation state, and iron-overloaded macrophages have
been detected in human chronic venous ulcers [63, 64]. In a
murine wound model iron overloaded macrophages were
shown to impair skin wound healing [63]. In diabetes, up-
regulation of proliferator-activated receptor (PPAR) c
activity, which is crucial for the switch in macrophage
phenotype, was impaired by sustained expression of IL-1b
in both mouse and human wounds. This results in deficient
M1–M2 transition and is associated with delayed wound
repair [65].
In the early inflammatory phase, neutrophils are abun-
dant in the wound and they are essential for
decontamination. However, if remaining in the wound over
time, neutrophils cause more harm than good. For example,
neutrophil proteases can degrade ECM as well as the
proteins important for repair, e.g., clotting factors, com-
plement, cytokines and immunoglobulin [66, 67]; they
produce free oxygen radicals resulting in oxidative stress,
which further damage tissue and delay healing [67].
Therefore, removal of neutrophils is prerequisite for
wounds to progress into the proliferative phase. According
to current knowledge, macrophages are the major players
responsible for removing neutrophils in the wound: they
induce neutrophil apoptosis [68]; then remove apoptotic
neutrophils by phagocytosis, a process termed efferocytosis
(Fig. 2) [69–72]. Interestingly, phagocytosis of neutrophils
is also a central element to induce the phenotype switch of
macrophages from pro-inflammatory M1 to a reparative
M2 phenotype [73]. The importance of efficient removal of
neutrophils by macrophages has been demonstrated in the
cases of chronic wounds. Impairment of efferocytosis of
macrophages, observed in diabetic wounds, prolongs the
inflammatory phase and delays healing [70]. Moreover, in
wounds of aged mice, the phagocytic function of macro-
phages was found deficient and associated with reduced
healing [74].
In the final phase of healing, macrophages also regulate
ECM content and remodeling by secretion of proteases and
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their inhibitors, such as matrix metalloproteinases (MMPs)
and tissue inhibitors of metalloproteinase (TIMPs) [75–77].
Interestingly, a recent study revealed the important role of
MMP-10 in regulating the collagenolytic activity of M2
macrophages, which is critical for scar resolution [41, 78].
A detailed discussion about the role of macrophages in
fibrolysis was provided elsewhere [79].
Actually, the crucial role of macrophages in skin wound
healing was established already in 1970s, when Leibovich
and Ross showed that depletion of macrophages signifi-
cantly delayed healing [80]. This finding has been
confirmed later by use of genetically modified mice,
allowing a highly specific depletion of macrophages in
wounds [81, 82]. Recently, Lucas et al. temporally and
selectively depleted macrophages at different phases of
wound healing. Their study shows that when macrophages
are absent in the inflammatory phase, re-epithelialization
and granulation tissue formation are reduced; whereas
depletion of macrophages in the proliferative phase results
in haemorrhage [83]. In both conditions, progression to the
following phases of wound repair fails [83].
Due to their crucial and pleiotropic roles during wound
healing, macrophages become attractive therapeutic tar-
gets. Many attempts to improve healing have used in situ
activation of macrophages in wounds (e.g., by topical
treatment of wound with macrophage activating agent
glucan [84]); recruitment of more macrophages (e.g., by
application of monocyte chemoattractant protein-1 (MCP-
1) to wounds [85]); or addition of exogenous macrophages
[86, 87]. Although these strategies have shown to posi-
tively impact wound healing, increased amount of
macrophages in wounds may imbalance the microenvi-
ronment and macrophages may switch to unfavorable
phenotypes, e.g., pro-inflammatory instead of reparative
phenotype [79]. Therefore, driving macrophages toward a
reparative phenotype in wounds seems a particularly
promising therapeutic approach.
Stromal microenvironment
Stromal cells, such as fibroblasts, not only repair wounds
by functioning as structure cells, they also actively regulate
the inflammatory events [88, 89]. Fibroblasts can condition
the local microenvironment and regulate the level and
kinetics of inflammation, to match the severity of the
damage. They interact with infiltrating inflammatory cells
through CD40 receptors, which further activate the NF-jB
signalling, causing fibroblasts to produce IL-6, IL-8,
cyclooxygenase-2 and hyaluronan, regulating the infiltra-
tion and behavior of immune cells [90]. Cytokine
deprivation induces apoptosis of inflammatory cells, which
often happen at the peak of the inflammatory response,
triggering resolution of inflammation [91]. Fibroblasts can
regulate apoptosis of infiltrating immune cells by produc-
ing potent survival factors, e.g., type I IFNs [92].
Moreover, increased expression of stromal derived factor
(SDF-1) from stromal cells and CXCR4 on infiltrating T
cells have been observed in inflamed skin. The interaction
between SDF-1 and CXCR4 may contribute to the inap-
propriate retention of immune cells in the skin [93].
Together, stromal cells play key roles in the inflammatory–
proliferative phase transition: in addition to their ‘repair’
role, stromal cells also contribute to resolution of inflam-
mation by withdrawal of survival factors and change of the
chemokine gradient, leading to apoptosis or exit of the
infiltrated immune cells from the skin.
Bioactive lipid mediators
Fatty acids are not only part of the structural lipids in the
skin; they are also the sources of a variety of bioactive
lipids, e.g., eicosanoids, endocannabinoids and sphin-
golipids, regulating the inflammatory response and
proliferation during wound healing [94].
Eicosanoids participate in initiation as well as resolution
of inflammation. Upon injury, prostaglandins and leuko-
trienes are produced by infiltrating immune cells, which
activate and amplify inflammation [95]. Prostaglandin E2
(PGE2) and D2 rapidly initiate the resolution process by
inducing the expression of lipid mediators with both anti-
inflammatory and pre-resolution functions, e.g., lipoxins
[96, 97], resolvins and protectins [98–100], a process
known as lipid-mediator class switch [97]. These lipid
mediators can selectively stop neutrophil infiltration;
increase monocyte recruitment and macrophage phagocy-
tosis; stimulate the expression of genes important for
antimicrobial defense; and promote the exit of phagocytes
from the inflamed sites [100–103]. In addition to regulation
of the inflammatory response, PGE2 has been shown to
increase keratinocyte proliferation and migration, thus
facilitating the transition to the proliferative wound healing
phase [104]. In humans, eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) supplementation increase
eicosanoids, thus promoting wound re-epithelialisation
[105]. Moreover, EPA and DHA have been shown to
dampen the inflammatory response by competing with
arachidonic acid in the lipoxygenase reaction, which leads
to reduced production of pro-inflammatory lipid mediators
[106].
Endocannabinoids, e.g., anandamide (AEA) and
2-arachidonoylglycerol (2-AG), bind to their G-protein-
coupled cannabinoid (CB) receptors and play anti-inflam-
matory roles in the skin [94]. For example, AEA suppresses
keratinocyte production of TNF-a and MCP-1 [107]. In
addition it inhibits T cell proliferation and production of
TNF-a and IFN-c by CD4? and CD8? T cells and IL-17
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by Th17 cells [108]. AEA has also been shown to suppress
mast cell numbers and activity in human skin [109]. 2-AG
increases the number of phagocytosing macrophages,
which leads to increased production of anti-inflammatory
cytokines, e.g., TGF-b1 and decreased output of pro-in-
flammatory cytokines, e.g., TNF-a by macrophages [73].
Moreover, the reactive oxygen species (ROS) production
by macrophages is also regulated by the balance of CB1
and CB2 activation, which is an important factor con-
tributing to the persistent inflammation in chronic wounds
and increasing the senescence of dermal fibroblasts [63,
110]. The specific role of endocannabinoids in skin wound
healing remains largely unexplored [94]. A relevant
research regarding periodontal healing has demonstrated
increased expression of CB1 and CB2 on fibroblasts and
macrophages in granulation tissue, as well as higher levels
of AEA in gingival crevicular fluid after wounding [111].
The activation of endocannabinoid signalling is important
for proliferation of gingival fibroblasts [111].
Sphingolipids play a broad role in the skin and some
sphingolipid metabolites have been postulated as potential
therapeutic targets for chronic wounds [94]. For example,
sphingosine-1-phosphate, produced by platelets at the
haemostasis phase of wound healing, has been shown to
promote keratinocyte migration and wound healing [112–
114]. Sphingosylphosphorylcholine increases proliferation
of human keratinocytes, and induces the production of
wound healing factors by human fibroblasts, e.g., connec-
tive growth tissue factor, IL-6 and plasminogen activator
inhibitor-1 [115–118].
Together, in addition to the protein mediators, i.e.,
cytokines and chemokines, bioactive lipid mediators are
important players regulating the transition from the
inflammatory to the proliferative phase of wound healing.
Redox signals
During normal metabolic processes reactive oxygen spe-
cies (ROS) are produced by all cells. In wounds, increased
amounts of ROS (e.g., superoxide anion, hydroxyl radicals,
singlet oxygen, hydrogen peroxide) are produced by
NADPH oxidase, an enzyme complex highly expressed in
inflammatory cells [119]. ROS can damage cells by oxi-
dation of cellular macromolecules, thus normally they are
rapidly detoxified by catalase, peroxidases, peroxiredoxins
and low molecular weight antioxidants [119]. The classical
view about the role of ROS in wound healing is to protect
the host against invading bacteria and other microorgan-
isms. However, recent studies reveal that low levels of
ROS can also function as mediators of intracellular sig-
nalling, playing crucial roles throughout the healing
process (reviewed in [120]). In the hemostasis phase, ROS
regulate blood coagulation, thrombosis and platelet
functions. In the inflammation phase, in addition to being
antimicrobial, ROS enhance the recruitment and function
of leukocytes. In the proliferation phase, low concentra-
tions of ROS have been shown to induce proliferation and
migration of epithelial cells. Moreover, Roy et al. found
that low concentrations of H2O2 supported healing by
promoting angiogenesis, whereas higher doses of H2O2
adversely influenced healing [121]. Tight control of redox
signals is crucial for the transition from inflammation to
proliferation during wound healing. Excessive amounts of
ROS cause oxidative stress, which damage cells and are
observed in chronic hard-to-heal wounds [119].
Negative regulation of TLR signalling
In skin wound healing, TLRs are the most well charac-
terized receptors on host cells, recognizing danger signals,
i.e., invading pathogens and tissue debris, and initiating
inflammatory response to remove these danger signals.
However, TLR-induced inflammation needs to be resolved
after removal of the danger signals, to allow wound healing
to proceed. The process of inflammation resolution
involves not only passive mechanisms, e.g., dissipation of
chemotactic gradient or initial danger signals, but also
active biochemical pathways [103]. In the case of TLR
signalling, a plethora of inhibitory mechanisms have been
discovered. Interestingly, most of these inhibitors are
induced through TLR activation, thus acting through a
negative-feedback loop to limit or turn off the TLR sig-
nalling [122]. The molecular mechanisms inhibiting TLR
signals (Fig. 1) include (a) interference of ligand binding,
e.g., soluble forms of TLR2 and TLR4 have been identified
to function as decoy, competing with the membrane-bound
forms of TLRs for ligands binding [123, 124]; (b) reduction
of TLR expression, e.g., anti-inflammatory cytokine TGF-b
suppresses the expression and function of TLR4 [125];
(c) degradation of TLRs, e.g., Triad3A can bind to the
cytoplasmic domain of TLR4 and TLR9 and promote their
ubiquitylation and degradation [126]; (d) inhibition of TLR
downstream signalling, e.g., suppressor of cytokine sig-
nalling 1 (SOCS1), interleukin-1 receptor-associated
kinase M (IRAKM), Toll-interacting protein (TOLLIP),
IRAK2c and IRAK2d have been shown to specifically
suppress the function of IRAK family of kinases; a cysteine
protease enzyme A20 has been shown to block TLR-me-
diated signalling by deubiquitylating TNF receptor-
associated factor (TRAF) 6; both IRAK and TRAF6 are the
key players in the TLR signalling pathways [122];
(e) change of structures of target genes through chromatin
remodelling and histone modification, e.g., H2AK119
ubiquitylation and H3K27 trimethylation inhibit the
expression of TLR-signal-targeted genes [127]. Recently,
TLR signalling has also been shown to be regulated by
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microRNAs at multiple levels, such as by targeting TLRs,
downstream signalling proteins, related regulatory mole-
cules, transcription factors as well as genes induced by
TLR signalling (e.g., cytokines), which was reviewed
elsewhere [128]. Deletion of genes encoding these inhibi-
tors results in a hyperinflamed state. For example, in mice
with deficient dual specificity phosphatase 1 (DUSP1)
expression, a MAPK phosphatase regulating TLR sig-
nalling, lipopolysaccharide (LPS) challenge induces
overshooting production of IL-6 and TNF-a and increased
infiltration of neutrophils [129].
Although mounting evidence has shown important roles
for TLR signalling in physiological wound healing, their
expression and function in chronic wounds remain largely
unknown [130]. In diabetic mouse, deletion of TLR2
decreased inflammation and accelerated wound closure,
suggesting that excessive TLR2 signalling may be detri-
mental to diabetic wounds [131]. In line with this finding,
Pukstad et al. reported that human non-healing venous
ulcers were associated with persistent activation of TLR2
and TLR4 signals [132]. It is unknown whether the
excessive TLR signalling in chronic wounds is due to the
impairment of inhibitory mechanisms as aforementioned,
which warrant future investigation.
Transcription factors
Transcription factors orchestrate the dynamic and complex
gene expression programs during wound healing. Here we
focus on the transcription mechanisms functioning in both
the inflammatory and proliferative phases of skin wound
healing, since changes of these mechanisms may affect
phase transition (Table 1). Extensive review regarding the
function of transcriptional factors in wound repair in gen-
eral can be found elsewhere [133–135].
Glucocorticoid receptors
As shown in several experimental and clinical studies, glu-
cocorticoids inhibit wound healing, which is due to their anti-
inflammatory and anti-mitotic effects on several cell types in
the wounds [136]. Glucocorticoids bind to and activate glu-
cocorticoid receptors (GRs), which migrate to the cell
nucleus, form homodimers and bind to specific DNA-binding
elements, i.e., glucocorticoid response elements, in the pro-
moter or enhancer regions of target genes [137]. In addition,
glucocorticoids regulate gene transcription through interact-
ing ligand-receptor monomers with members of the
activating protein 1 (AP-1) or NF-jB transcription factor
families [137]. To characterize the endogenous role of glu-
cocorticoid in wound healing, the mouse with GRs lacking
DNA-binding capacity was generated. In the wounds of
these mice, there are increased number of inflammatory cells
and high level of IL-1b. Also, formation of granulation tis-
sues in these mice is accelerated, with enhanced proliferation
and migration of fibroblasts, which is in line with the anti-
fibrogenic activity of glucocorticoids [138]. On the contrary,
keratinocyte-targeted overexpression of GRs leads to
delayed re-epithelialization and granulation tissue formation,
which is accompanied by reduced expression of pro-in-
flammatory cytokines and infiltration of granulocytes and
macrophages in the wounds [139].
Table 1 Transcription factors regulating inflammation and proliferation in skin wound healing
Transcription factor Inflammation Proliferation References
Re-epithelialization Granulation tissue Angiogenesis
GRs 2 2 2 [138, 139]
ARs 1 2 [140–143]
ERs 2 1 [144–147]
PPARs 2 1 [149–151]
AP-1 2 1 [152–155]
E2F1 1 1 [157]
Smad2 2 [159]
Smad3 1 2/1 [160–162]
Smad4 2 1/2 [163, 164]
Smad7 2 1 2 [165]
EGR1 1 1 1 1 [166–168]
HoxD3 1 1 1 [171]
HoxA3 1 1 1 [172]
HoxB13 1 2 1 [173, 174]
? positive regulation, - negative regulation
Transition from inflammation to proliferation: a critical step during wound healing 3869
123
Androgen and estrogen receptors
It has been observed that there are sex differences in wound
repair and males have a higher risk to develop chronic
wounds than females, which may be due to different effects
of androgens and estrogens on wound healing [140, 141].
Both androgens and estrogens bind to nuclear hormone
receptors, i.e., androgen receptors (ARs) and estrogen
receptors (ERs), which further interact with specific DNA-
binding elements, regulating target gene expression [134].
Castration of male mice or inhibition of the conversion of
testosterone to 5a-dihydrotestosterone (DHT) reduce the
production of pro-inflammatory cytokines and accelerate
re-epithelialisation of skin wounds, whereas treatment with
DHT decreases the migratory capacity of keratinocytes
[140, 142]. In line with this, treatment of wounds with
androgen receptor antagonist promotes healing, supporting
the negative effects of androgens on skin wound healing
[143]. In contrast to androgens, estrogen has been
demonstrated as a positive effector in wound healing. It has
been found that the wound heals slower in aged women and
also in ovariectomized young female rodents [144]. Topi-
cal application of estrogens or ER agonists in both aged
females and males can improve healing, which may be
partially due to the reduced expression of macrophage
migration inhibitory factor (MIF) and activation of ker-
atinocytes [145–147]. Together, the balance between
estrogen and androgen signalling may impact the outcome
of wound healing.
Peroxisome proliferator-activated receptors
The peroxisome proliferator-activated receptor (PPAR)
family, consists of three members PPARa PPARb/d and
PPARc, which are activated by polyunstaturated fatty acids
and different fatty acid derivatives [148]. Delayed wound
healing has been found in PPARa -/- and PPARb/d ?/-
mice, but not in PPARc ?/- mice [149]. Loss of PPARa
in mouse leads to exaggerated inflammation in wounds,
indicating its anti-inflammatory function [149]. Upon
wounding, PPARb/d has been shown to promote re-ep-
ithelialisation by increasing migration while decreasing
apoptosis of keratinocytes [149, 150]. PPARb/d also exerts
an anti-inflammatory effect by inducing the expression of
IL-1 receptor antagonist in fibroblasts [151].
Activator protein 1
Activator protein 1 (AP-1) leucine zipper transcription
factors, including hetero- or homodimers of the Fos, Jun
and CREB/ATF protein families, have been shown to be
up-regulated and/or activated after injury, which is
important for re-epithelialisation [152, 153]. Mice
heterozygous for the nuclear hormone receptor coactivator,
which activates c-Fos and c-Jun, develop chronic wounds
with reduced migration of keratinocytes [154]. Upon
injury, mice with deficient expression of JunB in the skin
show prolonged inflammation, epidermal hyperprolifera-
tion and aberrant differentiation [155].
E2F transcription factors
E2F transcription factor family is key regulators of cell
proliferation and embryogenesis [156]. The expression of
E2F1 and E2F2 has been found to be up-regulated in
wound-edge keratinocytes in healing human venous stasis
ulcers [157]. Accordingly, lack of E2F1 in mouse skin
results in delayed inflammatory response and re-epithe-
lialisation [157].
Smad proteins
TGF-b are pleiotropic cytokines regulating all phases of
wound healing [158]. TGF-b binds to the constitutively
active TGF-b type II receptor, which dimerizes, phospho-
rylates and activates type I receptor. Receptor dimerization
further activates Smads 2 and 3, which interact with Smad4
and enter the nucleus. The Smad complex binds to the
Smad-binding element on the target genes and regulates
their transcription. This signalling pathway is subjected to
sophisticated regulation, including the inhibitory Smads,
i.e., Smad6 and Smad7 [158]. It has been shown that
transgenic mice overexpressing Smad2 in basal ker-
atinocytes suffer from delayed wound healing, due to
reduced keratinocyte migration [159]. The role of Smad3 in
wound healing remains controversial: accelerated re-ep-
ithelialisation has been observed in Smad3 knockout mice,
which is accompanied with reduced inflammatory response
[160, 161]; however, Sumiyoshi et al. showed that subcu-
taneous injection of Smad-3-expressing adenovirus
enhanced re-epithelialization in a rabbit ulcer model [162].
In this study, the adenovirus mainly targeted fibroblasts,
whereas in Smad3 knockout mice all cells were affected,
which may account for the discrepancy between these
results. Smad4 knock-out mice have been established in
two independent studies: Owens et al. used a mouse model
with deficient Smad4 in multiple tissues/cell types, e.g.,
skin, erythrocytes, and B and T cells, and found that lack of
Smad4 resulted in delayed wound closure accompanied
with increased inflammation [163]; whereas Yang et al.
used a mouse model with specific deletion of Smad4 in
epidermal keratinocytes and showed enhanced re-epithe-
lialisation of wounds, which was mainly due to increased
keratinocyte proliferation [164]. The discrepancy of the
results indicates a complex role of Smad signalling
depending on the cellular context. The expression of
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inhibitory Smad, Smad7, was shown to be increased during
wound healing [165]. Transient overexpression of Smad7
in epidermal keratinocytes results in accelerated re-ep-
ithelialization due to increased keratinocyte proliferation
and migration; as well as reduced inflammation and
angiogenesis through indirect effects on the wound stroma
[165].
Early growth response 1
Early growth response 1 (EGR1) is a zinc finger tran-
scription factor essential for skin wound healing in adults.
Its deletion leads to impaired migration of keratinocytes
and inflammatory cells, reduced myofibroblast differenti-
ation and thus delayed healing [166, 167]. In contrast,
overexpression of EGR1 in wounds of adult mice and rats
increased re-epithelialisation, angiogenesis, collagen
deposition and wound contraction by up-regulating several
growth factors [168]. Moreover, transgenic mice overex-
pressing EGR1 in fibroblasts exhibited exuberant tissue
repair with increased collagen deposition and tensile
strength of the wounds [166]. Interestingly, although the
expression of EGR1 was increased in the wound edge of
E11.5 mouse embryos, its deletion did not affect embry-
onic wound healing [169]. Wound healing without scarring
(i.e., scarless healing) is observed only in embryos, and is
lost after birth. EGR1 may be mechanistically involved,
contributing to the difference between embryos and adults
in this respect.
Homeobox genes
Homeobox genes are a family of highly conserved tran-
scription factors regulating organ patterning during
development. Recently, several homeobox genes were
shown important in skin wound healing [170], such as
HoxA3 and HoxD3 improving healing in diabetic mice by
enhancing re-epithelialization, angiogenesis and collagen
deposition [171, 172]. However, HoxB13 negatively
affects wound healing: its overexpression delayed wound
healing, accompanied with prolonged inflammation [173];
whereas knockout of HoxB13 facilitates healing [174]. It is
noteworthy that HoxB13 is down-regulated in embryonic
scarless wound healing, but not in adult wounds [174],
indicating that differential expression of transcriptional
factors may account for the difference in healing between
embryo and adult.
Epigenetic regulatory mechanisms facilitating
the inflammation–proliferation transition
Epigenetics entails studying heritable changes of gene
expression, which result in alterations of the phenotype
without affecting the genomic DNA sequence [175]. Epi-
genetic mechanisms control gene expression at different
levels, i.e., covalent DNA and histone modifications (e.g.,
DNA methylation, histone methylation, phosphorylation
and acetylation), ATP-dependent and higher-order chro-
matin remodelling, as well as non-coding RNA and
microRNA-mediated regulation [176]. Different epigenetic
regulators exhibit dynamic expression patterns during
wound healing. For example, polycomb group (PcG) pro-
teins form polycomb repressive complexes (PRCs), which
are recruited to chromatin, modify histone and suppress
gene expression [177, 178]. During wound healing, the
expression of PcG proteins, e.g., enhancer of zeste 2
polycomb repressive complex 2 Subunit (EZH2), SUZ12
and EED are transiently downregulated, whereas histone
demethylases lysine (K)-specific demethylase 6B
(KDM6B) and 6A (KDM6A) are up-regulated [179]. This
indicates that the loss of PcG proteins-mediated suppres-
sion may transiently activate a group of genes,
participating in skin repair. However, the exact role of
epigenetic regulation in wound healing remains largely
unexplored.
Epigenetic modifications regulate the expression of
genes important for resolution of inflammation. It has
recently been shown that in dendritic cells and macro-
phages treated with LPS, loss of TET2, an enzyme that
catalyzes DNA demethylation, results in prolonged and
high expression of proinflammatory cytokines, including
IL-6 [180]. In the diabetic mouse model, there is enhanced
recruitment of histone methyltransferase SET7 to the
MCP-1 promoter region, which results in increased histone
H3-lysine 4 methylation and higher MCP-1 expression in
macrophages treated with TNF-a [181]. In diabetic
wounds, histone methylation, i.e., a repressive histone
methylation marker, H3K27me3, was found to be
decreased at the promoter of the IL-12 gene, which may
drive macrophages toward an inflammatory phenotype
[182].
Epigenetic modifications also play important roles in
regulating the proliferative phase of wound healing. It has
been found that deletion of PcG proteins EZH1 and EZH2
resulted in defective proliferation of stem cells and thus
impaired wound healing [183]. Also, administration of
DNA methyltransferases (DNMT) inhibitor, 5-aza20-
deoxycytidine, and histone deacetylase (HDAC) inhibitor,
Trichostatin A (TSA) to mice that had digit amputation
promotes wound healing by increasing proliferation of
stem cells [184]. Although studies directly examining the
role of epigenetic modifications in keratinocyte migration
are lacking, several research groups have reported that the
expression of MMPs, which are the enzymes degrading
ECM and allowing cell migration, are regulated by epi-
genetic mechanisms [185–188]. Moreover, HDAC has
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been shown to regulate both collagen production by
fibroblasts and TGF-b1-mediated myofibroblast transfor-
mation [189–192]. An altered pattern of DNA methylation
and histone acetylation has been identified in keloid
fibroblasts compared with fibroblasts from normal scars
[193]. Inhibition of HDAC with TSA leads to decreased
collagen synthesis and increased apoptosis of keloid
fibroblasts, indicating that epigenetic modification may be
a potential treatment for keloid [194]. Epigenetic mecha-
nisms also regulate angiogenesis. For example, inhibition
of HDAC attenuates VEGF signalling, which is important
for vascular morphogenesis and endothelial differentiation
[195]. PcG proteins, e.g., EZH2, are up-regulated and
involved in VEGF-mediated stimulation of angiogenesis
[196, 197].
Together, epigenetic regulators play important roles in
skin wound healing, especially in the inflammatory–pro-
liferative phase transition. Future research in this area may
identify epigenetic modulating drugs, which may be used
to treat impaired wound healing.
MicroRNAs
In the human genome, the majority of the transcriptional
output is constituted by RNAs that lack protein-coding
capacity [198, 199]. Intensive research in the recent decade
has revealed that these non-coding RNAs (ncRNAs)
function as important regulators of cellular physiology and
pathology, which makes them promising therapeutic and
diagnostic entities. MicroRNAs (miRNAs) are *22 nt
single-stranded RNAs and are the most well-known
ncRNAs to date. They incorporate into the RNA-induced
silencing complex (RISC) and bind to the 30 untranslated
region (UTR) of the target mRNA, which results in trans-
lational repression or degradation of target mRNAs [200].
MiRNA are proposed to regulate the majority of protein-
coding genes in humans [201]. Deregulation of miRNA
expression has been shown to contribute many diseases.
MiRNAs are key regulators controlling mammalian skin
development and morphogenesis, which has been demon-
strated by conditional knock-out of enzymes essential for
miRNA biogenesis, e.g., Dicer, Drosha or DGCR8 [202–
204]. To date, miRNAs have been shown to play important
roles in a variety of physiological and pathological pro-
cesses in the skin (reviewed in [205]), many of which
constitute key steps of wound repair, e.g., proliferation,
migration and angiogenesis. Recently, Ghatak et al.
revealed increased Dicer expression and bolstered miRNA
biogenesis at the later phase of healing process [206].
Keratinocyte-specific depletion of Dicer in mice prior to
wounding compromised wound closure, indicating a criti-
cal role for miRNA-mediated regulation of wound healing
[206]. Here we primarily focused on the miRNAs that have
been demonstrated in vivo to directly regulate the inflam-
matory and proliferative phases during skin wound healing
(Table 2).
MiRNAs regulate inflammation during wound healing
MiR-146a, miR-132 and miR-155 are the first miRNAs
identified to be associated with inflammation, induced in a
monocytic cell line treated with TLR4 ligand, LPS [207].
Recently, Meisgen et al. showed that miR-146a expression
was also increased in keratinocytes treated with TLR2,
TLR3 or TLR5 ligands [208]. During human skin wound
healing, miR-146a was down-regulated in the inflamma-
tory phase [209]. MiR-146a was found to negatively
regulate the innate immune response by targeting IRAK1,
IRAK2 and TRAF6 in monocytes, macrophages and epi-
dermal keratinocytes, suggesting that it may act as a brake
to prevent excessive inflammatory response and contribute
to resolution of inflammation [207, 210, 211]. In line with
this, decreased miR-146a and enhanced pro-inflammatory
target genes were observed in skin wounds of diabetic
mouse model [212].
MiR-132 is one of the top up-regulated miRNAs in the
inflammatory phase of human skin wounds in vivo, which
level further peaks in the subsequent proliferative phase
[209]. It has been shown that miR-132 decreases the pro-
duction of chemokines and the capability of keratinocytes
to attract leukocytes by suppressing the NF-jB signalling
pathway. Heparin-binding EGF-like growth factor (HB-
EGF) was identified as a key target mediating the biolog-
ical functions of miR-132 in keratinocytes [209].
MiR-155 is a critical regulator in the development of
immune cells [213]. The expression of miR-155 was highly
induced in macrophages stimulated with inflammatory
cytokines or TLR ligands [214]. Overexpression of miR-
155 decreases the expression of its target Src homology-2
domain-containing inositol 5-phosphatase 1 (SHIP1) in
hematopoietic cells, which leads to increased activation of
the kinase Akt during the cellular response to LPS [215]. In
line with this, Tili et al. reported that miR-155 enhanced
TNFa translation by targeting several LPS signalling
mediators in macrophages, e.g., Fas-associated death
domain protein (FADD), licB kinase epsilon (IKBKE), and
receptor (TNFR superfamily) interacting serine-threonine
kinase I (RIPK1) [216]. During skin wound healing, miR-
155 was found to be upregulated in wounds in the
inflammatory phase in both human and mouse [209, 217].
MiR-155 knock-out mice revealed enhanced wound clo-
sure compared to wild-type mice [217]. In line with this,
Yang et al. injected miR-155 antagomir into the wound
edge of mouse and found that antagonizing miR-155
locally improved healing by reducing fibrosis and inflam-
mation [218].
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MiR-21 has been proposed to function in dampening
inflammation [219]. MiR-21 is induced in macrophages by
resolving D1, which is an endogenous lipid mediator
generated during the resolution phase of acute inflamma-
tion. In addition, Das et al. revealed that miR-21 plays an
important role in regulating engulfment of apoptotic cells
by macrophages, which is prerequisite for the timely res-
olution of inflammation during wound healing [220]. The
expression of miR-21 is induced in macrophages by effe-
rocytosis, which tempers the LPS-induced inflammatory
response by silencing its targets phosphatase and tensin
homolog (PTEN) and glycogen synthase kinase (GSK) 3b.
Moreover, miR-21 silences programmed cell death protein
(PDCD) 4, favoring c-Jun-AP-1 activity, which in turn
results in elevated production of anti-inflammatory IL-10
by macrophages. Together, this work indicates that miR-
NAs are important in turning on an anti-inflammatory
phenotype in the postefferocytotic macrophage [220].
MiRNAs regulate the proliferative phase during wound
healing
Re-epithelialization In addition to its role in regulating
wound inflammation, miR-132 also promotes keratinocyte
growth through targeting HB-EGF and increasing the
activity of the signal transducer and activator of tran-
scription (STAT) 3 and MAPK signalling pathways [209].
Using mouse in vivo and human ex vivo wound model, we
showed that miR-132 blockade delayed healing, which was
accompanied by severe inflammation and deficient ker-
atinocyte proliferation. These results indicate that miR-132
is a critical regulator that may facilitate the transition from
the inflammatory to the proliferative phase during wound
healing [209].
MiR-21 is another player regulating both the inflam-
matory and proliferative phases of wound healing. MiR-21
was found up-regulated after wounding, mainly in acti-
vated and migrating epithelial cells of the epidermis and in
dermal mesenchymal cells [221, 222]. Yang et al. revealed
that miR-21 expression was induced by TGF-b1 in ker-
atinocytes, promoting keratinocyte migration by targeting
TIMP3 and T-cell lymphoma invasion and metastasis
(TIAM) 1 [222]. Antagonizing miR-21 locally in the
wound was shown to delay wound re-epithelialization
[222] and impair wound contraction and collagen deposi-
tion [221]. Interestingly, Pastar et al. found that miR-21
was overexpressed in human chronic non-healing wounds
compared to healthy skin. Local overexpression of miR-21
delayed re-epithelialization in a human skin ex vivo wound
model, as well as inhibited re-epithelialisation and granu-
lation tissue formation in a rat wound model, indicating the
importance of controlling the expression of miR-21 in
wounds [223]. In the same study, Pastar et al. also reported
that miR-130a, which is increased in human chronic
wounds, delayed re-epithelialisation [223].
In human skin wounds, miR-31 was shown to be grad-
ually up-regulated in wound-edge keratinocytes in the
inflammatory through the proliferative phase in compar-
ison with intact skin [224]. MiR-31 promoted keratinocyte
proliferation and migration by silencing epithelial mem-
brane protein 1 (EMP-1), suggesting a positive role in
regulating re-epithelialization [224].
In contrast, miR-483-3p, which level peaks at the final
stage of the wound closure, has been shown to inhibit
keratinocyte migration and proliferation by down-regulat-
ing its targets mitogen-activated protein kinase-activated
protein kinase (MK) 2, marker of proliferation Ki-67
(MKI67), and yes-associated protein (YAP) 1, representing
a novel mechanism for controlling keratinocyte growth
arrest in the final steps of re-epithelialization [225].
MiR-203 is the most abundant keratinocyte-specific
miRNA in the epidermis [226]. It controls stemness and is
fundamental for skin development and differentiation [227,
228]. In wounded mouse epidermis, miR-203 was found
down-regulated in the proliferating keratinocytes of the
‘migrating tongue’, whereas it is strongly expressed in the
differentiating cells of the skin outside the wound.
Accordingly, miR-203 was shown to suppress keratinocyte
proliferation and migration by regulating its targets Ras-
related nuclear protein (RAN), Ras association (RalGDS/
AF-6) and pleckstrin homology domains (RAPH) 1, Tumor
protein P63 (TP63) and LIM and SH3 protein (LASP) 1,
indicating its possible role in wound re-epithelialization
and epidermal homeostasis re-establishment of injured skin
[229].
In both human and mouse wound models, miR-99
family (miR-99a, miR-99b and miR-100) were found
downregulated in the inflammatory phase [209, 230]. Jin
et al. showed that downregulation of the miR-99 family
members leads to activation of AKT/mTOR signalling
pathway by targeting insulin-like growth factor 1 receptor
(IGF1R), mechanistic target of rapamycin (mTOR) and
V-Akt Murine Thymoma Viral Oncogene Homolog (AKT)
1, which in turn activates keratinocyte proliferation and
migration, and facilitates wound closure [230].
MiR-198 has been shown to suppress keratinocyte
migration by targeting and inhibiting diaphanous-related
formin (DIAPH) 1, plasminogen activator urokinase
(PLAU) and laminin gamma (LAMC) 2 [231]. Interest-
ingly, this miRNA is coded in the 30-untranslated region of
follistatin-like 1 (FSTL1) mRNA, which promotes cell
migration. Upon wounding, the expression of FSTL1 is
switched on, while the miR-198 expression is turned off,
due to the TGFb-mediated down-regulation of a KH-type
splicing regulatory protein (KSRP), which is essential for
processing the primary transcript into miR-198. Failure of
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this switch, as shown in chronic diabetic ulcers, in which
expression of miR-198 persists while FSTL1 is absent,
leads to impaired keratinocyte migration and re-epithe-
lialization [231].
In ischemic chronic wounds, high level of hypoxia
inducible factor-1a (HIF-1a) is present. HIF-1a has been
shown to induce the expression of miR-210, a miRNA
inhibiting keratinocyte proliferation by targeting cell-cycle
regulatory protein E2F3 [232]. Moreover, hypoxia-induced
miR-210 in endothelial cells has been shown to promote
angiogenesis by targeting Ephrin-A3 (EFNA3) [233].
Infection is another complication in chronic wounds,
where bacteria may form biofilms, which makes them
recalcitrant to antimicrobials and host defense. Using a
porcine burn wound model, Roy et al. showed that biofilm-
infection induce miR-146a and miR-106b in the wound-
edge tissue, which targets zona occludens (ZO)-1 and ZO-2
in keratinocytes to compromise tight junction function
[234]. This is relevant to the clinical observation that even
if an infected wound seems healed macroscopically it may
still be compromised by impaired epidermal barrier func-
tion and risk for re-infection.
Angiogenesis The roles of miRNAs in angiogene-
sis/neovascularization have been intensively investigated,
and was reviewed elsewhere (such as in [235]). Here
we focus only on the studies relevant for skin wound
healing.
In diabetes mellitus, the angiogenic potential of vas-
cular precursor cells is impaired. Wang et al. reported
that vascular precursor cells from mouse model of type 2
diabetes have lower miR-27b expression compared to the
normal littermate mice. Overexpression of miR-27b
improves the functions of vascular precursor cells in
diabetic mice, i.e., proliferation, adhesion, tube forma-
tion, and delays apoptosis by targeting thrombospondin-
1 (TSP-1), semaphorin 6A (SEMA6A), and pro-oxidant
protein p66Shc. Importantly, topical cell therapy with
diabetic vascular precursor cells overexpressing miR-
27b or direct local miR-27b delivery enhances diabetic
skin wound closure, with a concomitant augmentation of
wound perfusion and capillary formation [236]. How-
ever, in burn wounds, Lv et al. found that miR-27b
expression was decreased compared to intact skin. MiR-
27b targets stromal cell-derived factor-1a (SDF-1a), a
chemokine crucial for the recruitment of mesenchymal
stem cells (MSCs) from bone marrow reservoirs to repair
wounds. Injection of miR-27b into the burn wound edge
inhibited the mobilization of MSCs to the epidermis and
delayed healing [237].
Moreover, Chan et al. found that wounding transiently
down-regulated miR-200b in wound-edge endothelial cells,
which lead to increased expression of its targets, e.g.,
globin transcription factor binding protein 2 (GATA2) and
vascular endothelial growth factor receptor 2 (VEGFR2),
and switch on angiogenesis. This process is impaired in
diabetic wounds, in which excessive TNF-a increases miR-
200b expression, silences GATA2 and VEGFR2, and
suppresses angiogenesis [238].
Granulation tissue formation MiR-378a has recently
been shown to negatively affect skin wound healing:
inhibition of miR-378a enhances wound healing in vivo,
which leads to accelerated fibroblast migration and differ-
entiation by targeting vimentin (VIM) and b3 integrin
(ITGB3) [239]. As aforementioned, the increased expres-
sion of miR-21 during normal wound healing also
promotes fibroblast migration [240]. Moreover, miR-196a
has been shown to regulate collagen production by
fibroblasts through directly targeting collagen type 1 alpha
1 (COL1A1) and COL3A1 [241].
Studies using animal models and recent clinical trials
demonstrate that modulation of miRNA expression by
administration of specific miRNA mimics/inhibitors may
be used therapeutically [242]. Importantly, modulating
miRNAs may be a more effective strategy than tradi-
tional drugs targeting single proteins, since a single
miRNA can work as a switch, regulating an entire
functional network. Therefore, modulation of miRNAs
holds great promise to be effective treatments improving
wound healing.
Wound complications associated with deficient
transition from inflammation to proliferation
Accumulating evidence associates excessive inflammation
with major wound healing disorders, e.g., chronic wounds
and hypertrophic or keloid scars. This provides a rationale
for targeting the inflammatory–proliferative phase transi-
tion to improve the outcome of wound healing.
Chronic wound
Chronic wounds present a major, and increasing, health
and economic burden to our society [3]. It often occur in
patients with one or several underlying disorders, e.g.,
venous or arterial insufficiency, diabetes mellitus or sys-
temic inflammatory disease, all of which generate an
unfavorable milieu for the delicate repair process, trapping
wounds in a constant inflammatory state and failing to
progress through the normal healing stages [2]. Persisting
inflammatory cells, mainly neutrophils and macrophages,
generate large amount of proinflammatory cytokines and a
highly proteolytic microenvironment at the wound site [6].
Proinflammatory cytokines strongly induce the expression
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of various MMPs, and down-regulate the expression of
TIMPs [243, 244]. In addition, the neutrophil-originated
serine proteinases (SPs) are highly expressed in chronic
wounds [245, 246]. As a consequence, factors crucial for
wound healing, e.g., the major proteinase inhibitors (e.g.,
a1-proteinase inhibitor and a2-macroglobulin), compo-
nents of the provisional wound matrix (e.g., fibronectin and
vitronectin), growth factors (e.g., PDGF, VEGF) are
degraded or inactivated by proteolytic cleavage in chronic
wounds [246, 247]. Moreover, increased ROS in the
chronic wound, mainly from neutrophils, damages cell
membranes and structural proteins of the ECM, as well as
promotes the production of proinflammatory cytokines
(e.g., IL-1, IL-6, TNF-a), chemokines and proteolytic
enzymes (e.g., MMPs and SPs), amplifying the unre-
strained inflammation [248]. Non-healing wounds are often
complicated with bacterial infection, which sustains a
continuous influx of neutrophils and macrophages and
further delays wound repair [249]. Chronic wounds are
difficult to treat due to their complex nature and our limited
understanding of pathogenetic mechanisms. Up to one-
third of treated patients experience four or more episodes
of recurrence [3]. Therefore, identification of new thera-
peutic targets is needed. In this respect modification of
factors facilitating the transition from inflammation to
proliferation is likely a fruitful strategy for re-setting the
wound environment and activating tissue regeneration.
Bacteria and wound healing
Bacteria exist in all open skin wounds and the interaction
between bacteria and host ranges from contamination (i.e.,
the presence of non-replicating bacteria) through colo-
nization (i.e., the presence of replicating bacteria, but
absence of tissue damage) on to local infection (i.e., the
presence of replicating bacteria with subsequent host
injury), and finally to spreading infection which manifests
through cellulitis or septicaemia [249]. The transition from
colonization to invasive wound infection is determined by
the amount, the virulence and pathogenicity of the bacteria
as well as by the ability of the host to mount an effective
immune defense [249]. In chronic wounds, bacteria often
live in biofilms, which are communities of aggregated
bacteria embedded in a self-secreted extracellular
polysaccharide matrix. Biofilms protect bacteria from host
immune response and antibiotic treatment [250]. Sub-in-
fective levels of bacteria have been shown to enhance the
infiltration and function of neutrophils and mono-
cytes/macrophages, increase granulation tissue formation
and angiogenesis, as a consequence, accelerating wound
healing [249]. On the contrary, infection delays and
impairs wound healing. In the inflammation phase, infec-
tion increases consumption of complement proteins,
leading to decreased chemotaxis [251]. Bacterial products,
such as short chain fatty acids from anaerobic bacteria,
impair the functions of white blood cells [252]. Higher
amount of cytotoxic enzymes and ROS are produced,
increasing tissue damage. Bacterial exotoxins attack many
types of cells and cause tissue necrosis, which is exacer-
bated by local hypoxemia due to vessel occlusion [253]. In
the proliferation phase, bacterial metabolites inhibit ker-
atinocyte migration and digest dermal proteins and
polysaccharides, decreasing re-epithelialization [254, 255].
Infection also suppresses proliferation of fibroblasts and
causes disorganized collagen production, which lead to
decreased wound strength [251]. Bacterial endotoxins have
been shown to reduce collagen deposition and cross-link-
ing, which is associated with surgical dehiscence [256].
Moreover, bacterial endotoxins induce prolonged elevation
of proinflammatory cytokines, e.g., IL-1b and TNF-a,
which in turn increase MMP levels and decrease produc-
tion of growth factors [251]. Together, infection disrupts
the normal inflammation-proliferation phase transition and
may cause chronicity.
Scarring
Several lines of evidence directly link wound inflammation
with the extent of scar formation. For example, the early
fetal wound has minimal inflammation and exhibits scar-
less regeneration, whereas scar formation is exacerbated
when inflammation is provoked in fetal wounds [6]. It has
been shown that wounds in PU.1 null mouse, which is
genetically incapable of initiating inflammatory response,
heals rapidly and without scarring [257]. Moreover, oral
wounds with low infiltration of inflammatory cells also
heal quicker with minimal scar formation [258]. Excessive
dermal fibrosis and scarring, such as hypertrophic scars and
keloid, can develop after surgery, trauma, or even sponta-
neously in predisposed patients, which can cause physical
dysfunction and psychological distress. To date, there is no
satisfactory treatment available [11]. It has been shown that
persistent inflammation results in up-regulation of various
proinflammatory cytokines and chemokines, which further
induce the expression of growth factors (e.g., PDGF, TGF-
b1, activin), stimulating fibroblast proliferation, their dif-
ferentiation into myofibroblasts, and production of ECM in
a variety of fibrotic diseases, including hypertrophic scars
and keloids [259–261]. Therefore, efficient control of the
inflammatory–proliferative phase transition may be key to
minimize scar formation and prevent excessive scarring.
Age-related alterations in wound healing
With increasing age, both morphology and functions of the
skin change, due to intrinsic (e.g., hormone levels) and
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extrinsic factors (e.g., sun exposure). The aging-related
alterations in the skin result in delayed, but not defective,
wound healing [262]. In the hemostasis phase, aggregation
and degranulation of platelets are enhanced in the elderly
[263]. In the inflammation phase, increased neutrophil
response and delayed monocyte and T-cell infiltration in
the wounds have been observed in the aged compared with
young controls [264]. Moreover, the phagocytic activity of
wound macrophages in aged mice is decreased compared
with young mice, which may account for increased pro-
duction of proinflammatory cytokines, including IL-1, IL-
6, TNF-a, but decreased secretion of VEGF [74, 263, 265].
In the proliferation phase, diminished cell proliferation and
migration, decreased cytokine production, reduced
response to growth factors lead to delayed re-epithelial-
ization, angiogenesis and granulation tissue formation in
the elderly, which alterations may partially attribute to
impaired response to hypoxia (reviewed in [262]). This
inefficient inflammation-proliferation transition delays
wound healing in old people. However, in the remodeling
phase, reduced collagen turnover and increased fibroblast
senescence may result in less hypertrophic and cosmeti-
cally favorable scarring in old compared with young
individuals [262]. In addition to these age-related alter-
ations in the skin, factors associated with aging, e.g.,
reduced sex steroid hormones, immobilization, malnutri-
tion, medication and comorbidities (e.g., diabetes, venous
insufficiency, peripheral arterial disease) render the elderly
more susceptible to chronic wounds.
Animal models of wound repair
Wound repair is a biological process conserved in all
multicellular organisms. Most investigations on cell and
molecular mechanisms of wound healing are performed
using animal models, which are more experimentally
tractable than humans. The most commonly used animal
models are mice, from which we have gained significant
insights on more than 100 genes important for skin wound
healing over the last two decades [266]. Moreover, mice
models with impaired skin wound healing, e.g., leptin
receptor deficient mice (diabetes model), mice subjected to
ovariectomy (skin aging model) and skin flap ischemia
model, imitate some clinically relevant key aspects of
chronic wounds, providing us with useful tools to explore
the potential of novel therapeutic strategies. However, it is
important to bear in mind the difference in wound healing
between murine and human skin. For example, mouse skin
does not attach to underlying tissues, therefore the initial
reduction in would area is largely due to contraction of the
connective tissue, whereas in human re-epithelialization
plays a major role. Also mouse skin has much more hair
compared with human skin, which may affect healing
differently [11]. In preclinical trials of potential treatments,
pig models are often used due to the similarities between
pig and human skins. However, poor genetic tractability,
complicated surgical procedures and high cost limit their
use. Recently, Drosophila and zebrafish are used to
investigate mechanisms of fundamental tissue repair [267,
268]. These models offer unique possibilities, e.g., to per-
form live imaging, due to their translucency, and genome-
wide screen, due to their good genetic tractability and low
cost.
Concluding remarks and perspectives
Wound healing is a delicate and utterly complex process,
composed of a cascade of interlocking biological events,
among which the transition from inflammation to tissue
regeneration may be one of the most critical and defining
steps. Abnormal wound healing such as hard-to-heal ulcers
and excessive scarring is associated with inefficient or
failed transition between these two phases, indicating that
targeting the inflammatory–proliferative phase transition
could provide a new avenue for therapeutic development. It
has been suggested that suppression of inflammation may
be beneficial for promoting healing of chronic wounds and
reducing scarring. However, it may also increase the risk of
infection. Here we propose that modulation of factors that
can facilitate the resolution of inflammation and initiate
proliferation may be more advantageous for wound therapy.
In this review, we summarize recent research advances
focusing on the mechanisms controlling the inflammatory–
proliferative phase transition during skin wound healing,
including cellular factors, e.g., macrophages and fibrob-
lasts; molecular pathways, e.g., bioactive lipid mediators,
reactive oxygen species and TLR signalling; gene expres-
sion regulators, e.g., transcription factors and epigenetic
regulators, especially miRNAs. We propose that these
factors may be promising targets for development of more
effective wound therapy. However, for most of these fac-
tors we still do not know about their expression pattern and
function in the situation of abnormal wound healing, which
is prerequisite for designing targeted treatments. Moreover,
investigation of their role in wounds with different ethi-
ologies would be important for personalized wound
treatment. Hippocrates (c 400BC) once said that ‘healing is
a matter of time, but it is sometimes also a matter of
opportunity’. We believe that a better understanding of
mechanisms facilitating the transition from inflammation to
proliferation may offer opportunities for accelerating
wound healing and reducing scarring.
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